Results 201 to 210 of about 5,631,615 (309)

Private Equity-Acquired Residential Treatment Facilities vs Other For-Profit Facilities.

JAMA Health Forum
Havlik JL, Busch S, Hidalgo K, Mercado K, Zhu D, Jensen S, Zhu JM.   +6 more
europepmc   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Bacteriology and clinical outcomes of pleural infections in Singapore: an 8-year retrospective observational study. [PDF]

J Thorac Dis
Yong GKW, Wong JJJ, Zhang X, Lim Q, Lee H, Goh YSH.   +5 more
europepmc   +1 more source

Molecular cancer prevention: Intercepting disease

Molecular Oncology, EarlyView.
Oncological practice must evolve, from treating established tumours to proactive cancer interception before clinical manifestation. This will require mechanistic insight into tumour initiation, validated biomarkers of early disease development and redesigned clinical trials, enabling cancer interception to become a core pillar of oncology with the ...
Charlotte Grieco, Tej Pandya, Charles Swanton   +2 more
wiley   +1 more source

<i>Vibrio Albensis</i> Bacteraemia in a Decompensated Cirrhotic Patient with an Atypical Transmission Source. [PDF]

Eur J Case Rep Intern Med
Dinh TTH, Nguyen QP, Bui TT, Nguyen KN.
europepmc   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Private Equity Acquisition and Buprenorphine Prescribing.

JAMA Netw Open
Holdaway T, Busch SH, Reimer J, Beetham T, Fiellin DA, King M.   +5 more
europepmc   +1 more source

Deep brain stimulation in children with acquired dystonia. [PDF]

Front Neurol
Hagelschuer L, Koy A.
europepmc   +1 more source

Emerging strategies to target metastasis and therapy resistance in melanoma

Molecular Oncology, EarlyView.
Emerging studies propose new approaches to interfere with melanoma progression. In recognition of melanoma awareness month, at Molecular Oncology, we highlight recently published research articles, focusing on novel therapeutic targets driving metastatic spread and outlining different strategies to overcome resistance to BRAF inhibitors and anti‐PD‐1 ...
Amel Aziba
wiley   +1 more source